Trial Profile
A Phase II, Single-Arm Study of Pazopanib and Paclitaxel as First-Line Treatment for Subjects With Unresectable Stage III and Stage IV Melanoma
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 01 Oct 2023
Price :
$35
*
At a glance
- Drugs Pazopanib (Primary) ; Paclitaxel
- Indications Malignant melanoma
- Focus Therapeutic Use
- 05 Feb 2019 Status changed from active, no longer recruiting to completed.
- 12 Jan 2018 Planned End Date changed from 1 Jul 2018 to 1 Jan 2019.
- 12 Jan 2018 Planned primary completion date changed from 1 Jan 2018 to 1 Jan 2019.